vadimezan has been researched along with cyclic guanosine monophosphate-adenosine monophosphate in 11 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (cyclic guanosine monophosphate-adenosine monophosphate) | Trials (cyclic guanosine monophosphate-adenosine monophosphate) | Recent Studies (post-2010) (cyclic guanosine monophosphate-adenosine monophosphate) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 6 | 0 | 6 |
| 272 | 16 | 101 | 328 | 1 | 325 |
| Protein | Taxonomy | vadimezan (IC50) | cyclic guanosine monophosphate-adenosine monophosphate (IC50) |
|---|---|---|---|
| Stimulator of interferon genes protein | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, XL; You, QD; Zhang, H | 1 |
| Mikek, CG; Sintim, HO; Sooreshjani, MA; Wang, M | 1 |
| Bai, H; Gao, Y; Geng, M; Li, Z; Niu, J; Wang, X; Xie, Z; Xu, Y; Yang, Y; Zhang, Y; Zhou, B | 1 |
| Ding, C; Geng, M; Gu, W; Li, H; Shen, A; Song, Z; Wang, X; Xiao, R; Xie, Z; Zhang, A; Zhang, Y | 1 |
| Ascano, M; Barchet, W; Dai, P; Deng, L; Gaffney, BL; Gao, P; Hartmann, G; Jones, RA; Patel, DJ; Serganov, AA; Shuman, S; Tuschl, T; Wang, W; Zillinger, T | 1 |
| Aghaei, M; Downey, CM; Jirik, FR; Schwendener, RA | 1 |
| Arina, A; Beckett, M; Burnette, B; Chen, ZJ; Darga, T; Deng, L; Fu, YX; Gajewski, TF; Huang, X; Li, XD; Liang, H; Mauceri, H; Weichselbaum, RR; Xu, M; Yang, X | 1 |
| Deng, MJ; Du, XX; Han, MJ; Jiang, ZF; Li, LF; Su, XD; Tao, J; Ye, ZY; Zhang, H; Zhang, XY | 1 |
| Alpini, G; Botchlett, R; Cai, Y; Chen, L; Gao, X; Guo, T; Guo, X; Huo, Y; Ji, JY; Li, H; Li, P; Li, Q; Liu, M; Meng, F; Pei, Y; Shu, C; Woo, SL; Wu, C; Xiao, X; Xie, L; Xu, H; Zhang, KK; Zheng, J; Zhou, J | 1 |
| Damm-Ganamet, KL; Mirzadegan, T; Shih, AY | 1 |
| Ye, G; Zhang, C; Zhang, J | 1 |
2 review(s) available for vadimezan and cyclic guanosine monophosphate-adenosine monophosphate
| Article | Year |
|---|---|
Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Autoimmune Diseases; Binding Sites; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Membrane Proteins; Neoplasms; Protein Structure, Secondary; Signal Transduction | 2020 |
Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
Topics: | 2019 |
9 other study(ies) available for vadimezan and cyclic guanosine monophosphate-adenosine monophosphate
| Article | Year |
|---|---|
Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
Topics: 14-alpha Demethylase Inhibitors; Humans; Imidazoles; Immunity, Innate; Immunotherapy; Membrane Proteins; Neoplasms | 2022 |
Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Models, Molecular; Solubility; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA.
Topics: Animals; Antiviral Agents; Crystallography, X-Ray; Cyclic GMP; Humans; Interferon Regulatory Factor-3; Interferon Type I; Membrane Proteins; Mice; Models, Molecular; Mutagenesis; Nucleotides, Cyclic; Protein Conformation; Signal Transduction; Structure-Activity Relationship; Xanthones | 2013 |
DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Cell Polarity; Clodronic Acid; Humans; Inflammation; Liposomes; Lung Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Transgenic; Necrosis; Neovascularization, Pathologic; Nucleotides, Cyclic; Phenotype; ras Proteins; Subcutaneous Tissue; Tumor Suppressor Protein p53; Xanthones; Xenograft Model Antitumor Assays | 2014 |
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Topics: Adaptive Immunity; Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Cells, Cultured; Cross-Priming; Dendritic Cells; DNA; Immunity, Innate; Interferon-beta; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Differentiation Factor 88; Neoplasms; Nucleotides, Cyclic; Nucleotidyltransferases; Radiation, Ionizing; Receptor, Interferon alpha-beta; RNA Interference; RNA, Small Interfering; Signal Transduction; Xanthones | 2014 |
Rat and human STINGs profile similarly towards anticancer/antiviral compounds.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antiviral Agents; Humans; Hydrophobic and Hydrophilic Interactions; Membrane Proteins; Mice; Models, Molecular; Molecular Conformation; Nucleotides, Cyclic; Protein Binding; Rats; Signal Transduction; Structure-Activity Relationship; Xanthones | 2015 |
Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation and Regulates Proinflammatory Responses Distinctly from STING Activation.
Topics: Adipocytes; Animals; Diet, High-Fat; Hepatocytes; Humans; Immunity, Innate; Interferon Type I; Macrophages; Membrane Proteins; Mice; Nucleotides, Cyclic; Obesity; Phosphorylation; Protein Serine-Threonine Kinases; Xanthones | 2017 |
Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA.
Topics: Animals; Apoproteins; Humans; Hydrogen Bonding; Membrane Proteins; Mice; Molecular Dynamics Simulation; Nucleotides, Cyclic; Protein Conformation; Xanthones | 2018 |
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Interferons; Lapatinib; Male; Membrane Proteins; Mice, Inbred BALB C; Nucleotides, Cyclic; Pyridines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Vascular Endothelial Growth Factor Receptor-2; Xanthones; Xenograft Model Antitumor Assays | 2021 |